Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
about
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective StudyEvolution of lymphoma staging and response evaluation: current limitations and future directions.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Clinical Trials in the Genomic Era.Report of the 6th International Workshop on PET in lymphoma.FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.Hodgkin lymphoma: A review and update on recent progress.18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.Interim FDG-PET in lymphoma, a questionable practice in hematology.Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).Targeting Immune System Alterations in Hodgkin Lymphoma.[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialApplication of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma
P2860
Q33820910-4FD6592F-D5F3-42E0-A852-87FDEEB54929Q33849498-7887182A-1BB5-42E7-B341-18BEC6390EA0Q38671671-65261D02-3510-4716-B68B-C2C9815F5B0AQ38737416-4F7284BC-6387-4297-B380-EE429FA6A817Q38905607-6B015766-0FE9-4A3A-ADEA-A4E5BEAA2065Q38926460-203E35E1-B3BD-4979-AEC7-5BE5B002A368Q39259769-A88BFD3E-3E0E-4004-BF5B-3C89C004F320Q41269380-55724144-D8CA-4483-A4B3-5A5C6D81F62CQ47563022-F1AFD806-6231-4F75-8F10-908FCBF2EB55Q47568589-7DDE0AEA-5C7D-475F-B64C-0089BFAAE2F4Q47807176-07A754FC-19AC-4CC7-BF7D-B27E4F8E07CBQ47808320-7F81B667-79B4-402D-B988-1625CCC701BDQ48105701-FF80A843-00F4-45E1-8706-BCA2C855D2A0Q48212826-B618A7CE-B913-4BBA-975F-CB38027B5BE1Q48227716-CB8C39C3-0743-424A-BF02-C7439354DA12Q48265648-3759E60F-C714-4B39-8A79-FB51814EDA8FQ48316502-929AD792-D561-4751-ADC0-1CA61DC6100FQ48618984-C7B4B6F1-FCD1-4731-B569-71DAF62A6B96Q48669191-FD36FB90-C8A5-4D16-B183-BA1D2E74D59CQ48689919-015313F6-6B3F-41C4-B03F-F98408B52402Q50271165-6FC10CDF-F00F-4E0A-B51F-993DAFC9B501Q52929230-54455508-CB59-42F5-9819-58FB9422FC86Q53123844-BD590642-F1FF-4B73-8A2B-692210FD9312Q55220794-B2548993-6E7F-4B4C-950B-80B1883E3B06Q55495617-0EA609E2-0EE4-4899-8AF2-C1538EFA98B1Q56383260-C58FA6CF-1B38-46F0-9DF9-E53A2E890EC7Q57820488-3597B2D8-66EF-4DF3-89F0-26704D8DA697
P2860
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Refinement of the Lugano Class ...... a of immunomodulatory therapy.
@en
type
label
Refinement of the Lugano Class ...... a of immunomodulatory therapy.
@en
prefLabel
Refinement of the Lugano Class ...... a of immunomodulatory therapy.
@en
P2093
P1433
P1476
Refinement of the Lugano Class ...... ra of immunomodulatory therapy
@en
P2093
Bruce D Cheson
Heather A Jacene
Larry Schwartz
Leo I Gordon
Philippe Armand
Ranjana Advani
Stephen Ansell
P304
P356
10.1182/BLOOD-2016-05-718528
P407
P577
2016-08-29T00:00:00Z